1st Department of Internal Medicine Multiprofile Hospital for Active Treatment HristoBotev Vratsa Bulgaria

AOP Orphan Pharmaceuticals Vienna Austria

CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences Vienna Austria

Clinic of Internal Medicine Hematology and Oncology University Hospital Brno Brno Czech Republic

Clinical Hematology Clinic Multiprofile Hospital for Active Treatment Sveta Marina Varna Bulgaria

Department of Clinical Hematology University Hospital Hradec Kralove Hradec Kralove Czech Republic

Department of Hematology Faculty of Medicine University of Debrecen Debrecen Hungary

Department of Hematology Regional Treatment and Diagnostics Hematology Centre Cherkasy Regional Oncology Centre Cherkasy Ukraine

Department of Hematology Yaroslavl Regional Clinical Hospital Yaroslavl Russia

Department of Hematology Zealand University Hospital Roskilde University of Copenhagen Copenhagen Denmark

Department of Internal Medicine 1 Division of Hematology and Blood Coagulation Medical University Vienna Vienna Austria

Department of Internal Medicine 2 Kaposi Mor County Teaching Hospital Kaposvar Hungary

Department of Laboratory Medicine Medical University of Vienna Vienna Austria

Medical University of Plovdiv Plovdiv Bulgaria

Teaching Unit of the Hematology Department University Hospital in Krakow Krakow Poland

Université de Paris AP HP Hôpital Saint Louis Centre d'Investigations Cliniques INSERM CIC1427 Paris France

Zobrazit více v PubMed

Kiladjian JJ, Cassinat B, Chevret S, Turlure P, Cambier N, Roussel M, et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood. 2008;112:3065–72. doi: 10.1182/blood-2008-03-143537. PubMed DOI

Verger E, Soret-Dulphy J, Maslah N, Roy L, Rey J, Ghrieb Z, et al. Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo. Blood Cancer J. 2018;8:94. doi: 10.1038/s41408-018-0133-0. PubMed DOI PMC

Kiladjian JJ, Giraudier S, Cassinat B. Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone. Leukemia. 2016;30:776–81. doi: 10.1038/leu.2015.326. PubMed DOI

Utke Rank C, Weis Bjerrum O, Larsen TS, Kjaer L, de Stricker K, Riley CH, et al. Minimal residual disease after long-term interferon-alpha2 treatment: a report on hematological, molecular and histomorphological response patterns in 10 patients with essential thrombocythemia and polycythemia vera. Leuk Lymphoma. 2016;57:348–54.. doi: 10.3109/10428194.2015.1049171. PubMed DOI

Hasselbalch HC, Holmstrom MO. Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure? Semin Immunopathol. 2019;41:5–19. doi: 10.1007/s00281-018-0700-2. PubMed DOI PMC

Daltro De Oliveira R, Soret-Dulphy J, Zhao L-P, Marcault C, Gauthier N, Verger E, et al. Interferon-alpha (IFN) therapy discontinuation is feasible in myeloproliferative neoplasm (MPN) patients with complete hematological remission. Blood. 2020;136:35–6. doi: 10.1182/blood-2020-141223. DOI

Pedersen RK, Andersen M, Knudsen TA, Sajid Z, Gudmand-Hoeyer J, Dam MJB, et al. Data-driven analysis of JAK2V617F kinetics during interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms. Cancer Med. 2020;9:2039–51. doi: 10.1002/cam4.2741. PubMed DOI PMC

Gisslinger H, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M, et al. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. Lancet Haematol. 2020;7:e196–e208. doi: 10.1016/S2352-3026(19)30236-4. PubMed DOI

Barosi G, Birgegard G, Finazzi G, Griesshammer M, Harrison C, Hasselbalch HC, et al. Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood. 2009;113:4829–33. doi: 10.1182/blood-2008-09-176818. PubMed DOI

Mosca M, Hermange G, Tisserand A, Noble R, Marzac C, Marty C, et al. Inferring the dynamics of mutated hematopoietic stem and progenitor cells induced by IFNα in myeloproliferative neoplasms. Blood. 2021;138:2231–43.. doi: 10.1182/blood.2021010986. PubMed DOI PMC

Gisslinger H, Zagrijtschuk O, Buxhofer-Ausch V, Thaler J, Schloegl E, Gastl GA, et al. Ropeginterferon alfa-2b, a novel IFNalpha-2b, induces high response rates with low toxicity in patients with polycythemia vera. Blood. 2015;126:1762–9. doi: 10.1182/blood-2015-04-637280. PubMed DOI PMC

Karantanos T, Moliterno AR. The roles of JAK2 in DNA damage and repair in the myeloproliferative neoplasms: opportunities for targeted therapy. Blood Rev. 2018;32:426–32.. doi: 10.1016/j.blre.2018.03.007. PubMed DOI

Alvarez-Larrán A, Bellosillo B, Pereira A, Kerguelen A, Hernández-Boluda JC, Martínez-Avilés L, et al. JAK2V617F monitoring in polycythemia vera and essential thrombocythemia: clinical usefulness for predicting myelofibrotic transformation and thrombotic events. Am J Hematol. 2014;89:517–23. doi: 10.1002/ajh.23676. PubMed DOI

Shirane S, Araki M, Morishita S, Edahiro Y, Sunami Y, Hironaka Y, et al. Consequences of the JAK2V617F allele burden for the prediction of transformation into myelofibrosis from polycythemia vera and essential thrombocythemia. Int J Hematol. 2015;101:148–53. doi: 10.1007/s12185-014-1721-9. PubMed DOI

Abu-Zeinah G, Krichevsky S, Cruz T, Hoberman G, Jaber D, Savage N, et al. Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival. Leukemia. 2021;35:2592–601.. doi: 10.1038/s41375-021-01183-8. PubMed DOI PMC

ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options

Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment